CSL Behring UK Ltd announced today that the European Medicines Agency has expanded the administration options for HizentraA a-1 4, human normal immunoglobulin, SCIg, 20% liquid, to include dosing once every two weeks .
http://www.businesswire.com/news/topix/20131205005486/en
http://www.businesswire.com/news/topix/20131205005486/en
No comments:
Post a Comment